Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

Combination Therapy Appears Helpful For Short-Term Treatment Of Insomnia; Cognitive Behavior Therapy May Be Better For Long-Term
For patients with persistent insomnia, a combination of cognitive behavior therapy (CBT) and the medication zolpidem for 6 weeks was associated with improvement in sleep, although for a longer treatment period CBT alone was more beneficial, according to a study in the May 20 issue of JAMA.
generic viagra online
Legislation To Overhaul U.S. Foreign Aid Introduced
Senator John Kerry (D-Mass.), chairman of the Senate Foreign Relations Committee, and ranking member, Senator Richard Lugar (R-Ind.), on Tuesday "introduced a bill to overhaul the U.S. system for providing global development aid," the Boston Globe reports (Smith, 7/29). The legislation was also introduced by Senators Robert Menendez (D-NJ) and Bob Corker (R-Tenn.), according to a release from Menendez"s office (7/28).
News of the day
Could New Government Regulations Lead To Increased Use Of Physical Restraints?
Over the past 20 years, the health care system has made tremendous progress in reducing the use of physical restraints among hospitalized elderly patients, a positive change that has had numerous numerous ripple effects, improving outcomes, maintaining mobility and preserving dignity and independence for these individuals.
Diagnostics

FDA Accepts For Review Spectrum's Response On ZEVALIN As A Class 1 Submission, And Establishes September 7, 2009 As Decision Date

Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI), a commercial stage biotechnology company with a focus on oncology, announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the resubmission to the Company"s supplement to the biologics license application for ZEVALIN (ibritumomab tiuxetan) in the first line consolidation setting on July 8, 2009. The FDA considers the review as a Class 1 submission to their complete response letter of July 2, 2009. Therefore, the user fee goal date is September 7, 2009. ZEVALIN is currently FDA approved and marketed by Spectrum Pharmaceuticals for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin"s Lymphoma, including patients who have rituximab-refractory follicular non-Hodgkin"s Lymphoma. About ZEVALIN® ZEVALIN® (ibritumomab tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated as part of the ZEVALIN therapeutic regimen for treatment of relapsed or refractory, low-grade or follicular B-cell NHL, including patients with rituximab-refractory follicular NHL. ZEVALIN is also indicated, under accelerated approval, for the treatment of relapsed or refractory, rituximab-naç¯ve, low-grade and follicular NHL based on studies using a surrogate endpoint of overall response rate. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL. Rare deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab (Rituxan®) infusions. Yttrium-90 ZEVALIN administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most serious adverse reactions of the ZEVALIN therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to ZEVALIN therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients (8 to 34 months after treatment). ZEVALIN should only be used by health care professionals qualified by training and experience in the safe use of radionuclides. For more information on ZEVALIN, patients and healthcare professionals can visit http://www.ZEVALIN.com. Spectrum Pharmaceuticals


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009